Painful mononeuropathy of the lateral femoral cutaneous nerve (LFCN) was first described by Bernhardt in 1878, the symptom complex initially comprised of pain, numbness, tingling, and paresthesia in the anterolateral thigh that was not associated with a surgical procedure
If you want the broader landscape (and the list of other peptides driving search interest), see Metos internal piece: 14 Peptides Are About to Become Legal Again What This Means for Your Health. Who should consider AOD-9604 (and who shouldnt) Consider it only if your expectations are realistic AOD-9604 may be worth a conversation if you are: Already doing the fundamentals (protein, resistance training, sleep) Not seeking massive scale weight loss Looking at fat-loss support rather than appetite suppression Intolerant of GLP-1s and exploring alternatives (with the understanding that alternatives are usually less powerful) Avoid it if You have significant obesity and need a high-efficacy therapy (GLP-1/GIP class is typically far more impactful) (PubMed) Youre hoping it will melt fat without dietary alignment Your plan depends on unverified sources or research peptide suppliers Youre in a drug-tested sport environment (WADA prohibition is relevant) (wada-ama.org) Practical expectations (what most people want to know) How fast does it work
At Perfect B in Doral, FL, we dispense the protocol, the manual, and the follow-up
It is important to emphasize that these recommendations should not be considered concrete rules as there is significant individual variability of how athletes may respond to the manipulation of these variables
